Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lei Chen"'
Publikováno v:
Journal of Medical Economics. 17:89-98
Molecular monitoring of chronic myeloid leukemia (CML) has been associated with improved clinical outcomes during tyrosine kinase inhibitor therapy (TKI), yet recent studies have demonstrated its use is far below published guidelines. This study soug
Autor:
Mansoor N. Saleh, Lei Chen, Kavita R. Sail, Sally Haislip, Tamara Hess, James H. Jackson, Solveig G. Ericson, James Gilmore, Joyce Sharpe
Publikováno v:
Current Medical Research and Opinion. 30:529-536
Real-world treatment and monitoring patterns have not been well documented among imatinib-treated chronic phase chronic myeloid leukemia (CP-CML) patients. Thus, we evaluated these patterns and responses to imatinib in CP-CML patients.This retrospect
Autor:
Solveig G. Ericson, Eric Q. Wu, Jipan Xie, Elias Jabbour, Lei Chen, Annie Guerin, Andrew P. Yu
Publikováno v:
Current Medical Research and Opinion. 28:1831-1839
Monitoring treatment response is an integral part of chronic myeloid leukemia (CML) treatment. The guidelines recommend regular monitoring using standard methods (e.g., real-time quantitative polymerase chain reaction based on the international scale
Publikováno v:
Current Medical Research and Opinion. 28:1155-1162
To compare adherence to second-generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib in patients with imatinib resistant or intolerant chronic myeloid leukemia (CML) receiving second-line therapies.Two U.S. administrative claims databa